Clinical trial NCT00773357
Conditions: Smoking
Keywords: smoking lapse behavior guanfacine
Sponsor: Yale University
Start date: 2008-10-01; Completion date: 2021-07-31
Enrollment: 100 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of this study is to examine whether guanfacine will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking and non-treatment seeking daily smokers.

Detailed description:

Arms: arm 1: guanfacine 3mg/day arm 2: placebo control
Interventions: intervention 1: guanfacine intervention 2: placebo
Intervention descriptions: intervention 1: 3 mg/day, with 3-week lead-in medication period. The starting dose is 0.5 mg/day for days 1-3, followed by 1.5mg/day for days 4-7, followed by 2 mg/day for days 8-12, followed by 2.5 mg/day for days 13-15, followed by 3 mg/day from day 16 to remainder of study. 5-day taper at end of study. intervention 2: placebo

Protocol documents:
Prot_SAP_000.pdf: 
STUDY PROTOCOL INCLUDING STATISTICAL ANALYSIS PLAN 
 
OFFICIAL TITLE: Modeling Stress-precipitated Smoking Behavior for Medication Development 
 
BRIEF TITLE: Stress and smoking behavior (Sherry McKee, PhD, PI) 
 
CLINICALTRIALS.GOV ID: NCT00773357 
 
PROTOCOL DATE: January 31 2022 
 
 


Identifying effective medications for the treatment of tobacco smoking remains a high priority as 
problems associated with tobacco use continues to be major public health problem. One promising, yet 
relatively unexplored avenue for medication development for smoking are therapeutics that target 
stress-reactivity. Several lines of evidence suggest that stress is a primary mediator of tobacco use and 
relapse. Preclinical research demonstrates that noradrenergic pathways are involved in stress-induced 
consumption and reinstatement to nicotine, as well as nicotine-related reinforcement and withdrawal, 
and that their manipulation may be of potential therapeutic benefit for tobacco use.  
Guanfacine is an alpha2a adrenergic receptor agonist known to attenuate stress-induced reinstatement 
to nicotine and other drugs of abuse in preclinical studies. Guanfacine rescues the prefrontal cortex 
from detrimental effects of stress and improves working memory, attention, and behavioral control.  
 
STUDY OBJECTIVE 
To conduct a Phase II human laboratory study evaluating the effect of guanfacine on smoking behavior. 
Using a double-blind, placebo-controlled, we randomized adults with nicotine dependence to 
guanfacine (3mg/day or placebo) to evaluate whether guanfacine increases the ability to resist smoking. 
Following titration to steady state medication levels over a 3-week period, subjects completed two 
laboratory sessions to evaluate drinking smoking behavior. 
 
STUDY DESIGN AND METHODS 
This study was a double-blind, placebo controlled, parallel-group design, to compare immediate release 
guanfacine (3.0mg/day) to placebo (0mg/day) in adults meeting criteria for nicotine dependence. This 
study consisted of an intake session, a physical exam, and two laboratory sessions following titration to 
steady state levels. Ability to resist smoking was modelled as the delay to start smoking in exchange for 
monetary reinforcement. Primary outcome measure time to delay smoking. 
 
ELIGIBILTY 
Minimum Age: 18 Years   
Maximum Age: 60 Years   
Sex: 
All   
Gender Based:   
Accepts Healthy Volunteers: 
Yes   
Criteria: 
Inclusion Criteria: 
• 
ages 18-60 
• 
able to read and write in English 


• 
smokers 
Exclusion Criteria: 
• 
any significant current medical conditions that would contraindicate smoking 
• 
current Diagnostic and Statistical Manual IV (DSM-IV) abuse or dependence of other substances, 
other than nicotine (or caffeine) dependence 
• 
positive test result at intake appointments on urine drug screens conducted for opiates, cocaine, 
or benzodiazepines 
• 
women who are pregnant or nursing 
• 
suicidal, homicidal or evidence of severe mental illness 
• 
participants prescribed any psychotropic drug in the 30 days prior to study enrollment 
• 
blood donation within the past 6 weeks 
• 
participants who have engaged in a quit attempt in the past 3 months 
• 
specific exclusions for administration of guanfacine not already specified include: Hypotensive 
individuals with sitting blood pressure below 90/50 mmHG; EKG evidence at baseline screening 
of any clinically significant conduction abnormalities, including a Bazett's corrected QT interval 
(QTc) >450 msec for men and QTc>470 msec for women; known intolerance for guanfacine 
 
STATISTICIAL CONSIDERATIONS 
PRIMARY HYPOTHESIS: During the laboratory session, 3mg/day guanfacine vs placebo will increase the 
time to resist smoking. Anova of medication condition was used to evaluate time to delay smoking.